SGLT-2 inhibitors as second-line therapy in type 2 diabetes

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	678-679
Number of pages	2
Journal	The Lancet Diabetes and Endocrinology
Volume	2
Issue number	9
Early online date	16 Jun 2014
DOIs	https://doi.org/10.1016/S2213-8587(14)70135-4
Publication status	Published - Sept 2014

ASJC Scopus subject areas

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{26e8e20a3a694d1aa89ac4c2d3e46e0d,

title = "SGLT-2 inhibitors as second-line therapy in type 2 diabetes",

author = "Tahrani, {Abd A.}",

year = "2014",

month = sep,

doi = "10.1016/S2213-8587(14)70135-4",

language = "English",

volume = "2",

pages = "678--679",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - SGLT-2 inhibitors as second-line therapy in type 2 diabetes

AU - Tahrani, Abd A.

PY - 2014/9

Y1 - 2014/9

UR - http://www.scopus.com/inward/record.url?scp=84908339916&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(14)70135-4

DO - 10.1016/S2213-8587(14)70135-4

M3 - Comment/debate

C2 - 24948512

AN - SCOPUS:84908339916

SN - 2213-8587

VL - 2

SP - 678

EP - 679

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 9

ER -